You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Malignant Lymphomas

Showing 1 - 25 of 4,656
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Infection in Malignant Lymphomas Participating in

Completed
  • Malignant Lymphoma
  • +2 more
  • No intervention
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-Sen University Cancer Ce
Apr 22, 2023

Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

Not yet recruiting
  • Marginal Zone Lymphoma
  • (no location specified)
Nov 6, 2023

s From HIV Infection, KSHV Infection, Viral-Related

Recruiting
  • HIV
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 25, 2023

    Tumors Malignant Trial in Shanghai (AK117)

    Active, not recruiting
    • Neoplasms Malignant
    • Shanghai, Shanghai, China
      FuDan University Shanghai Cancer Center
    Oct 8, 2022

    Lymphoma Diagnosed at Nimes University Hospital From 1999 to

    Recruiting
    • Lymphoma, Malignant
      • Nîmes, France
        CHU Nimes
      May 12, 2022

      Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

      Recruiting
      • Solid Tumor, Adult
      • +6 more
      • TP53-EphA-2-CAR-DC
      • +3 more
      • Beijing, Beijing, China
        Biotherapeutic Department of Chinsese PLA Gereral Hospital
      Nov 29, 2022

      Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor

      Recruiting
      • Advanced Lymphoma
      • +13 more
      • BET Bromodomain Inhibitor ZEN-3694
      • +2 more
      • New Haven, Connecticut
        Yale University Cancer Center LAO
      Jun 29, 2022

      Advanced Malignant Tumors Lymphomas Trial in United States (IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody

      Recruiting
      • Advanced Malignant Tumors Lymphomas
      • IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
      • Los Angeles, California
      • +3 more
      Aug 23, 2022

      Advanced Malignancies Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL95)

      Recruiting
      • Advanced Malignancies
      • Recombinant Humanized Monoclonal Antibody MIL95
      • Beijing, China
        Beijing Cancer Hospital
      Feb 14, 2022

      Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

      Active, not recruiting
      • Malignant Non-Hodgkin Lymphomas
      • CD34+ cell selection
      • Berne, Switzerland
        Department for Medical Oncology; University Hospital/Inselspital
      Jul 29, 2021

      Malignant Lymphomas Treated With MabThera® SC in Everyday

      Completed
      • Lymphoma, B-Cell, Lymphoma, Follicular
        • Essen, Germany
          Universitätsklinikum Essen; Klinik für Hämatologie
        Oct 29, 2020

        Malignant Solid Tumors, Lymphoma, Ovarian Cancer Trial in Canada, United States (AZD5153, Olaparib)

        Completed
        • Malignant Solid Tumors
        • +5 more
        • Sarasota, Florida
        • +3 more
        May 5, 2021

        Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

        Recruiting
        • Colorectal Carcinoma
        • +21 more
        • Dual X-ray Absorptiometry
        • +2 more
        • Birmingham, Alabama
        • +18 more
        Jan 30, 2023

        Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Tumor Trial run by the NCI (p97

        Withdrawn
        • Aggressive Non-Hodgkin Lymphoma
        • +3 more
        • p97 Inhibitor CB-5339 Tosylate
        • Bethesda, Maryland
        • +1 more
        Aug 27, 2021

        CD20-positive B Cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62 Injection)

        Completed
        • CD20-positive B Cell Non-Hodgkin Lymphoma
        • Recombinant Humanized Monoclonal Antibody MIL62 Injection
        • Beijing, Beijing, China
          Chinese Academy of Medical Sciences (CAMS) & Peking Union Medica
        Jun 15, 2021

        Malignant Solid Tumors, Lymphomas Trial in Muenster (tTF-NGR)

        Completed
        Has Results
        • Malignant Solid Tumors
        • Lymphomas
        • tTF-NGR
        • Muenster, NRW, Germany
          University Hospital Muenster
        Nov 12, 2020

        Adenoid Cystic Skin Carcinoma, Adnexal Carcinoma, Anaplastic Large Cell Lymphoma, ALK-Negative Trial in United States

        Recruiting
        • Adenoid Cystic Skin Carcinoma
        • +38 more
        • Biopsy
        • +6 more
        • Los Angeles, California
        • +35 more
        Jan 31, 2023

        Advanced Lymphoma, Advanced Malignant Solid Tumor, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Trial (Entinostat,

        Withdrawn
        • Advanced Lymphoma
        • +16 more
        • (no location specified)
        Sep 25, 2020

        Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases Trial in Hollywood, Boston, Chapel Hill (Brentuximab Vedotin, CHEP)

        Active, not recruiting
        • Lymphoma
        • +2 more
        • Brentuximab Vedotin
        • CHEP
        • Hollywood, Florida
        • +3 more
        Nov 30, 2022

        Lymphoma Trial in Berne (Brentuximab Vedotin, BeEAM Regimen)

        Recruiting
        • Lymphoma
        • Brentuximab Vedotin
        • BeEAM Regimen
        • Berne, Switzerland
          Department for Medical Oncology University Hospital/Inselspital
        Feb 4, 2022

        Lymphoma, B-Cell, Lymphoma, Hodgkin, Exercise Trial in Copenhagen (Resistance Exercise Training)

        Recruiting
        • Lymphoma, B-Cell
        • +8 more
        • Resistance Exercise Training
        • Copenhagen, Denmark
          Rigshospitalet
        Oct 25, 2022

        Extranodal Lymphoma or Lymphoma of Rare Pathological Types

        Not yet recruiting
        • Lymphoma
        • +8 more
        • No interventions need to be specified for this study
        • Shanghai, China
          Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
        Jun 15, 2023

        Advanced Solid Malignancies, Malignant Lymphomas Trial in Tainan, Taipei (Gemcitabine HCl Oral Formulation)

        Completed
        • Advanced Solid Malignancies
        • Malignant Lymphomas
        • Gemcitabine HCl Oral Formulation
        • Tainan, Taiwan
        • +2 more
        Jul 3, 2019

        Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

        Active, not recruiting
        • Aggressive B-Cell Non-Hodgkin Lymphoma
        • fractionated first dose rituximab
        • Geneva, Switzerland
          University Hospital Geneva
        Apr 21, 2023

        Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

        Recruiting
        • Advanced Malignant Solid Neoplasm
        • +44 more
        • Biopsy
        • +23 more
        • Birmingham, Alabama
        • +166 more
        Feb 2, 2023